Sancak Banu
Hacettepe University Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey.
Mikrobiyol Bul. 2011 Jul;45(3):565-76.
After the report of first case of methicillin-resistant Staphylococcus aureus (MRSA) in 1961, MRSA become a major problem worldwide. Over the last decade MRSA strains have emerged as serious pathogens in nosocomial and community settings. Glycopeptides (vancomycin and teicoplanin) are still the current mainstay of therapy for infections caused by MRSA. In the last decade dramatic changes have occurred in the epidemiology of MRSA infections. The isolates with reduced susceptibility and in vitro resistance to vancomycin have emerged. Recently, therapeutic alternatives such as quinupristin/dalfopristin, linezolid, tigecycline and daptomycin have been introduced into clinical practice for treating MRSA infections. Nevertheless, these drugs are only approved for certain indication and resistance has already been reported. In this review, the new information on novel drugs for treating MRSA infections and the resistance mechanisms of these drugs were discussed.
自1961年首例耐甲氧西林金黄色葡萄球菌（MRSA）病例报告以来，MRSA已成为全球范围内的一个主要问题。在过去十年中，MRSA菌株已成为医院和社区环境中的严重病原体。糖肽类药物（万古霉素和替考拉宁）仍然是目前治疗MRSA引起感染的主要药物。在过去十年中，MRSA感染的流行病学发生了巨大变化。出现了对万古霉素敏感性降低和体外耐药的分离株。最近，诸如奎奴普丁/达福普汀、利奈唑胺、替加环素和达托霉素等治疗替代药物已被引入临床实践用于治疗MRSA感染。然而，这些药物仅被批准用于某些适应症，并且已经有耐药性的报道。在本综述中，讨论了治疗MRSA感染的新型药物的新信息以及这些药物的耐药机制。
